Hypothesis

With advancing age, bone hydroxyapatite (HA) crystals grow larger and become more stoichiometrically stable, increasing their affinity for γ‑carboxylated osteocalcin (Gla‑OCN). This enhanced binding depletes the pool of undercarboxylated, bioactive osteocalcin (Glu‑OCN) that normally restrains HA crystal maturation and signals to osteocytes through the GPRC6A receptor. Consequently, reduced Glu‑OCN signaling diminishes osteocyte calcium responses to mechanical load, contributing to the loss of mechanosensitivity observed in aged bone.

Mechanistic Basis

• HA crystal surface chemistry: Larger, more crystalline HA presents fewer defects and a higher density of phosphate groups, which strengthens the electrostatic interaction with the Gla domains of OCN (see vitamin K‑dependent carboxylation enables HA binding).
• OCN carboxylation shift: Elevated vitamin K availability or reduced warfarin‑like activity in aging shifts the Gla‑OCN/Glu‑OCN ratio toward the matrix‑bound form, as suggested by the correlation between increased HA crystallinity and OCN sequestration (Ageing modulates ultrastructural composition of bone matrix).
• Loss of Glu‑OCN signaling: Glu‑OCN inhibits HA nucleation and crystal growth (OCN inhibits mineralization and regulates HA crystal maturation). When sequestered, this brake is released, permitting runaway HA maturation.
• Impact on osteocyte mechanotransduction: Glu‑OCN engages GPRC6A on osteocytes, triggering downstream pathways (e.g., PI3K‑Akt) that amplify fluid‑shear‑induced calcium fluxes. Reduced Glu‑OCN therefore attenuates these signals, decreasing sclerostin suppression and impairing load‑adaptive bone formation.

Testable Predictions

1. In aged mice, histochemical staining will show higher colocalization of Gla‑OCN with HA compared to young bone, while immunostaining for Glu‑OCN in the pericellular space will be reduced.
2. Pharmacologic reduction of vitamin K epoxide reductase activity (low‑dose warfarin) in aged mice will increase the Glu‑OCN fraction, decrease HA crystallite size (measured by synchrotron XRD), and restore osteocyte calcium transients to mechanical vibration.
3. Ocn‑null mice rescued with a Glu‑OCN‑specific peptide (lacking the Gla domain) will exhibit smaller HA crystals and improved mechanosensitive bone formation despite lacking total OCN.
4. Direct addition of purified Glu‑OCN to isolated osteocyte networks from aged donors will augment fluid‑flow‑evoked calcium spikes, an effect blocked by a GPRC6A antagonist.

Experimental Approach

• Sample preparation: Collect femoral trabecular bone from young (3 mo) and aged (24 mo) C57BL/6 mice; process sections for immunohistochemistry (Gla‑OCN, Glu‑OCN) and backscattered electron imaging for HA crystal morphology.
• Biochemical assays: Extract bone protein pools; quantify carboxylated vs. undercarboxylated OCN by ELISA using isoform‑specific antibodies.
• Mechanical stimulation: Seed osteocyte‑enriched cultures on collagen‑coated membranes; apply oscillatory fluid flow (1 Hz, 0.5 Pa) and record Fluo‑4 calcium signals.
• Intervention groups: Aged mice receive (i) vehicle, (ii) low‑dose warfarin (0.5 mg/kg/day), (iii) Glu‑OCN peptide (10 µg/kg/day), or (iv) combination, for 8 weeks.
• Outcome measures: HA crystallite size (XRD peak width), mineral‑to‑matrix ratio (FTRI), osteocyte lacunar density, serum carboxylated/uncarboxylated OCN, bone formation rates (dynamic histomorphometry), and mechanical testing (three‑point bending).

If the predictions hold, the data would support a causal link between HA‑driven OCN sequestration, depleted Glu‑OCN signaling, and age‑related loss of osteocyte mechanosensitivity—offering a mechanistic rationale for vitamin K modulation strategies that aim to preserve the Glu‑OCN pool rather than merely maximize carboxylation.